Analysts Set Expectations for MiMedx Group FY2025 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of MiMedx Group in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings per share of $0.33 for the year. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share.

Separately, StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG opened at $9.14 on Wednesday. MiMedx Group has a 1 year low of $5.47 and a 1 year high of $10.14. The firm has a market cap of $1.34 billion, a P/E ratio of 16.62 and a beta of 1.96. The stock has a fifty day moving average price of $9.19 and a two-hundred day moving average price of $7.43. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.02. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $84.06 million during the quarter, compared to analysts’ expectations of $81.00 million. During the same period last year, the firm posted $0.05 earnings per share.

Hedge Funds Weigh In On MiMedx Group

A number of hedge funds have recently modified their holdings of the stock. Jane Street Group LLC increased its stake in MiMedx Group by 133.6% in the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock worth $1,806,000 after purchasing an additional 174,797 shares in the last quarter. Barclays PLC increased its position in shares of MiMedx Group by 163.9% in the third quarter. Barclays PLC now owns 262,449 shares of the company’s stock worth $1,550,000 after acquiring an additional 163,005 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of MiMedx Group by 88.6% during the third quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company’s stock valued at $145,000 after acquiring an additional 11,557 shares during the period. Harbor Capital Advisors Inc. lifted its position in shares of MiMedx Group by 299.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after acquiring an additional 770,744 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in MiMedx Group by 47.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock worth $8,958,000 after purchasing an additional 413,443 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.